Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis

J Med Vet Mycol. 1993;31(3):207-18. doi: 10.1080/02681219380000261.

Abstract

A submicron amphotericin B (AmB) sterile emulsion with a mean droplet size of approximately 100 nm was prepared. The emulsion was stable at 4 degrees C over a period of 4 months. The acute toxicity results showed that the maximum tolerated dose of the AmB emulsion was 2.0 mg kg-1 as compared to 0.5 mg kg-1 for a commercial deoxycholate suspension, Fungizone. Efficacy evaluations of submicron AmB emulsion compared to Fungizone were performed in a murine candidiasis model using either a single or a multiple daily dose administration of 0.4 mg kg-1. Survival (100%) was observed up to 15-18 days post-infection in mice treated with AmB emulsion or Fungizone, while all control non-treated animals had died after 9 days in both single and multi-treatment experiments. Survival (50%) was obtained after 35 days in the single treatment, and 40 days in the multi-treatment, experiment with AmB emulsion, while treatment with Fungizone gave 50% survival after 15 and 20 days, respectively. The overall results indicate that in murine candidiasis, treatment with AmB submicron emulsion was more effective than Fungizone, suggesting a potential therapeutic application.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / pharmacology
  • Amphotericin B / therapeutic use*
  • Amphotericin B / toxicity
  • Animals
  • Candida albicans / drug effects*
  • Candidiasis / drug therapy*
  • Deoxycholic Acid
  • Dose-Response Relationship, Drug
  • Emulsions
  • Evaluation Studies as Topic
  • Follow-Up Studies
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Treatment Outcome

Substances

  • Emulsions
  • Deoxycholic Acid
  • Amphotericin B